Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows

v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
6 Months Ended
Nov. 30, 2018
Nov. 30, 2017
Cash flows from operating activities:    
Net loss $ (28,718,950) $ (22,575,959)
Adjustments to reconcile net loss to net cash used by operating activities:    
Amortization and depreciation 243,772 178,282
Amortization of debt issuance costs 19,589 282,129
Amortization of discount on convertible notes 117,534 1,172,995
Inducement interest related to warrant exercise   826,252
Interest expense associated with derivative liabilities 0 0
Change in fair value of derivative liabilities 466,412 (466,934)
Stock-based compensation 1,510,486 529,617
Loss on extinguishment of convertible note 1,519,603  
Deferred income tax benefit (2,826,919)  
Changes in current assets and liabilities:    
(Increase) decrease in prepaid expenses (1,807,629) 907,606
Increase in accounts payable and accrued expenses 3,283,113 6,256,192
Net cash used in operating activities (26,192,989) (12,889,820)
Cash flows from investing activities:    
Furniture and equipment purchases (2,262)  
Net cash used in investing activities (2,262)  
Cash flows from financing activities:    
Proceeds from sale of common stock and warrants 23,463,585 7,050,651
Proceeds from warrant exercises   1,647,500
Proceeds from convertible note payable 5,000,000 4,888,500
Payment of offering costs (2,727,418) (1,175,575)
Net cash provided by financing activities 25,736,167 12,411,076
Net change in cash (459,084) (478,744)
Cash, beginning of period 1,231,445 1,775,583
Cash, end of period 772,361 1,296,839
Non-cash investing and financing transactions:    
Financing costs associated with placement agent warrants   70,383
Accrued interest converted into note payable 225,245  
Debt discount associated with convertible notes payable 700,000 $ 1,574,628
Derivative liability associated a convertible note payable 1,284,998  
ProstaGene, LLC    
Non-cash investing and financing transactions:    
Common stock issued for acquisition $ 11,558,000